-
Mashup Score: 1UNIFI Long-Term Extension Shows Safety, Efficacy of Ustekinumab for Ulcerative Colitis Through 4 Years - 3 month(s) ago
Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Data from a phase 3 trial of CT-P43 in patients with moderate to severe plaque psoriasis offers additional insight into the comparative effects of the biosimilar relative to ustekinumab.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Data from a phase 3 trial of CT-P43 in patients with moderate to severe plaque psoriasis offers additional insight into the comparative effects of the biosimilar relative to #ustekinumab. https://t.co/cdamudisOV
-
-
Mashup Score: 0Amgen, J&J settle ustekinumab patent lawsuit in potential biosimilar market shake-up - 10 month(s) ago
Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing. Meanwhile, the rheumatology world awaits the debut of other ustekinumab biosimilars in the market — and what they may portend for patient care moving forward
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Johnson & Johnson(@JNJNews) has settled its lawsuit with @Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States. https://t.co/YnEPFHUbdU #rheumatology #ustekinumab
-
-
Mashup Score: 0Ustekinumab Demonstrates Favorable Safety Profile in Patients With IBD - 12 month(s) ago
Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and ustekinumab.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and #ustekinumab. https://t.co/VDRsmfQdwu #DDW2023 https://t.co/K1FtxoOCqH
-
-
Mashup Score: 0Vedolizumab, ustekinumab induce similar rates of clinical response, remission in Crohn’s - 12 month(s) ago
CHICAGO — Biologic-naive patients treated with vedolizumab and ustekinumab for Crohn’s disease had similar rates of clinical response and remission, although mucosal healing and biologic treatment persistence differed at 36 months.“Crohn’s disease is characterized by chronic gastrointestinal inflammation that often requires lifelong treatment,” Marc Ferrante, MD,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Biologic-naive patients treated with #vedolizumab and #ustekinumab for #Crohns disease had similar rates of clinical response and remission, although mucosal healing and biologic treatment persistence differed at 36 months. #DDW23 @DDWMeeting https://t.co/t0X0mTmTGz
-
-
Mashup Score: 0Selecting the Right Biologic Treatment for Psoriasis Patients - 1 year(s) ago
An American Academy of Dermatology Reading Room selection
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
ICYMI: Researchers investigated the drug survival associated with effectiveness and safety of adalimumab, #ustekinumab, secukinumab, ixekizumab, and #guselkumab in patients with #psoriasis. #AADReadingRoom @AADskin #dermatology Read more: https://t.co/M0lXfSULgl https://t.co/msRoNPpuSq
-
-
Mashup Score: 0Concomitant Methotrexate Does Not Increase Efficacy of Ustekinumab in Patients with Psoriatic Arthritis - 1 year(s) ago
Results from the MUST trial reported that ustekinumab monotherapy was just as effective in treating psoriatic arthritis as treatment with ustekinumab plus methotrexate.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
#Ustekinumab, an IL-12 and IL-23 inhibitor, effectively treated #PsoriaticArthritis, regardless of methotrexate co-therapy, based on changes in the Disease Activity Score 28 (DAS28). https://t.co/ktxg3wIOmk
-
-
Mashup Score: 0Concomitant Methotrexate Does Not Increase Efficacy of Ustekinumab in Patients with Psoriatic Arthritis - 1 year(s) ago
Results from the MUST trial reported that ustekinumab monotherapy was just as effective in treating psoriatic arthritis as treatment with ustekinumab plus methotrexate.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Results from the MUST trial reported that #ustekinumab monotherapy was just as effective in treating #PsoriaticArthritis as treatment with ustekinumab plus methotrexate. https://t.co/DNSvWIQJlw
-
-
Mashup Score: 0Concomitant Methotrexate Does Not Increase Efficacy of Ustekinumab in Patients with Psoriatic Arthritis - 1 year(s) ago
Results from the MUST trial reported that ustekinumab monotherapy was just as effective in treating psoriatic arthritis as treatment with ustekinumab plus methotrexate.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Results from the MUST trial reported that #ustekinumab monotherapy was just as effective in treating #PsoriaticArthritis as treatment with ustekinumab plus methotrexate. https://t.co/LeR3BQyyFw
-
-
Mashup Score: 0
Objectives To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. Methods PsABio ([NCT02627768][1]), a prospective, observational study, followed patients with PsA prescribed first-line to third-line ustekinumab or a TNFi. Persistence and effectiveness (achievement of clinical…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
What is the long-term effectiveness and persistence of #ustekinumab and TNFi in PsA? Results from the PsABio just published: ▶️ similar persistence for both treatments ▶️ similar rates of effectiveness outcomes achieved ▶️ equivalent safety 🔗 https://t.co/FdGCfqjL9a https://t.co/QAZdFS1nTP
-
Final efficacy and safety results from the UNIFI long-term extension study of subcutaneous maintenance therapy with #ustekinumab for ulcerative colitis showed clinical and endoscopic outcomes were maintained through 4 years. Learn more: https://t.co/k6BqL3yyzq https://t.co/D5Q338GqvX